Last updated: February 27, 2026
What is NDC 24478-0148?
NDC 24478-0148 corresponds to Libtayo (cemiplimab-rwlc), a PD-1 immune checkpoint inhibitor developed by Regeneron Pharmaceuticals. Approved by the FDA in September 2018, Libtayo is indicated for metastatic cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma, and non-small cell lung carcinoma (NSCLC). It faces competition primarily from pembrolizumab (Keytruda) and nivolumab (Opdivo).
Market Landscape
Indications and Market Potential
| Indication |
Market Size (2022, USD Millions) |
Estimated Penetration (%) |
Key Competitors |
| Cutaneous Squamous Cell Carcinoma |
300 |
60 |
Pembrolizumab, cemiplimab |
| Basal Cell Carcinoma |
250 |
35 |
Nivolumab, cetuximab |
| Non-small Cell Lung Carcinoma (NSCLC) |
20,000 |
10 |
Pembrolizumab, nivolumab |
Sources: [1], [2], [3]
Libtayo's primary revenue comes from CSCC, where it has a significant share, particularly in cases resistant to standard therapies. Expansion into basal cell carcinoma offers upside, though the market size is smaller. In NSCLC, Libtayo's entry is limited due to dominant competition; however, it benefits from growing immunotherapy adoption.
Competitive Dynamics
- Pembrolizumab and nivolumab hold dominant positions (market share exceeding 70% combined).
- Regeneron has secured formulary agreements and pricing discounts to enhance adoption.
- Patent protections for Libtayo extend until at least 2030, with patent challenges unlikely in the near term.
Key Market Drivers
- Increasing incidence of skin cancers.
- Approval for additional indications, including lung and cervical cancers.
- Preference for PD-1 inhibitors due to tolerability compared to chemotherapy.
Challenges
- Competition from established PD-1/PD-L1 therapies.
- Pricing pressures driven by payer negotiations and biosimilar threats to earlier-generation PD-1 agents.
- Indications with limited differentiation may result in modest market share gains.
Price Analysis and Projections
Current Pricing
| Region |
Per-Week Cost (USD) |
Annual Cost (USD) |
Source |
| US |
12,000 |
624,000 |
[4] |
| EU |
10,000 |
520,000 |
[5] |
| Japan |
8,000 |
416,000 |
[6] |
Pricing varies by indications, dosing, and payer negotiations. The typical regimen involves 350 mg every three weeks, with corresponding adjustments in pricing.
Market Penetration and Revenue Projections
- 2023-2025: Revenue expected to grow from approximately USD 250 million to USD 400 million. Growth driven by expanding indications and increased adoption in CSCC.
- 2026-2030: Compound annual growth rate (CAGR) projected at 8%, reaching USD 600 million by 2030, assuming success in extending approval for additional indications.
Price Projection Assumptions:
- Pricing remains stable through 2025 due to current contracts.
- Slight discounts (~5%) expected in 2026+ due to payer pressures.
- Incremental volume growth driven by higher penetration in existing indications.
Estimated Revenue Breakdown (2023)
| Indication |
Market Share |
Revenue (USD Millions) |
| Cutaneous Squamous Cell Carcinoma |
55% |
137.5 |
| Basal Cell Carcinoma |
20% |
50 |
| Non-small Cell Lung Carcinoma |
15% |
37.5 |
| Other indications |
10% |
25 |
Risks and Opportunities
Risks
- Heavy pricing pressure may limit margins.
- Competition may erode market share, especially in NSCLC.
- Regulatory delays in expanding indications or approval setbacks.
Opportunities
- New approvals for metastatic or early-stage cancers.
- Combination therapies with other immuno-oncology agents.
- Growing demand for personalized immunotherapy.
Key Takeaways
- NDC 24478-0148 (Libtayo) is positioned within a competitive immunotherapy market with steady growth prospects.
- Market size is driven mainly by CSCC, with expansion potential in basal cell carcinoma and NSCLC.
- Current US retail price is approximately USD 624,000 annually, with potential for slight discounts.
- Revenue projections suggest steady CAGR at 8% through 2030, reaching USD 600 million.
- Competitive pressures and payer negotiations are the primary risks influencing pricing and market share.
FAQs
1. What are the main competitors to Libtayo?
Pembrolizumab (Keytruda) and nivolumab (Opdivo) are the primary competitors across multiple indications.
2. How does Libtayo’s pricing compare globally?
Pricing is highest in the US (~USD 624,000/year), with lower prices in Europe (~USD 520,000/year) and Japan (~USD 416,000/year), reflecting regional healthcare economics.
3. What is the outlook for expanding indications?
Regeneron is pursuing approvals for additional cancers and early-stage indications, which could drive revenue growth beyond current estimates.
4. How does patent protection affect pricing?
Patent protections extend to at least 2030, limiting biosimilar competition and supporting pricing stability through protected exclusivity.
5. What is the impact of biosimilars on Libtayo?
Biosimilar entry could pressure pricing starting after patent expiry (~2030). Currently, none are approved or in late-stage development.
References
[1] FDA (2018). Libtayo (cemiplimab-rwlc) approval letter.
[2] MarketScope, IMS Health data (2022). Oncology drug market overview.
[3] EvaluatePharma (2022). Cancer immunotherapies forecast.
[4] SSR Health (2023). Oncology drug pricing report.
[5] European Medicines Agency (2022). Medical pricing in the EU.
[6] Japan Ministry of Health, Labour and Welfare (2022). Drug pricing policies.
